These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2873740)

  • 1. Long-term use of probucol in the multifactorial primary prevention of vascular disease.
    Miettinen TA; Huttunen JK; Naukkarinen V; Strandberg T; Vanhanen H
    Am J Cardiol; 1986 Jun; 57(16):49H-54H. PubMed ID: 2873740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality.
    Miettinen TA; Huttunen JK; Naukkarinen V; Strandberg T; Mattila S; Kumlin T; Sarna S
    JAMA; 1985 Oct; 254(15):2097-102. PubMed ID: 4046137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of probucol on xanthomata regression in familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Yokoyama S; Funahashi T; Yamamura T; Kishino B
    Am J Cardiol; 1986 Jun; 57(16):29H-35H. PubMed ID: 3728307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
    Miettinen TA; Huttunen JK; Ehnholm C; Kumlin T; Mattila S; Naukkarinen V
    Atherosclerosis; 1980 Jun; 36(2):249-59. PubMed ID: 6773532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical management of hyperlipidemia and the role of probucol.
    Davignon J
    Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
    Kuo PT; Wilson AC; Kostis JB; Moreyra AE
    Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of probucol on triton induced hyperlipidemias in CFY rats.
    Krishnamurthy A; Thapar GS; Shridhar DR
    Artery; 1985; 13(2):87-94. PubMed ID: 4084069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of probucol on hyperlipidemic patients with cardiac allografts.
    Anderson JL; Schroeder JS
    J Cardiovasc Pharmacol; 1979; 1(3):353-65. PubMed ID: 94402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study.
    Blacher J; Evans A; Arveiler D; Amouyel P; Ferrières J; Bingham A; Yarnell J; Haas B; Montaye M; Ruidavets JB; Ducimetière P;
    J Hypertens; 2004 Feb; 22(2):415-23. PubMed ID: 15076202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDL cholesterol and beta-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial.
    Miettinen TA; Vanhanen H; Huttunen JK; Naukkarinen V; Mattila S; Strandberg T; Kumlin T
    Br J Clin Pharmacol; 1982; 13(Suppl 2):431S-434S. PubMed ID: 6125196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma carnitine and lipid-lowering drugs.
    Nestruck AC; Pande SV; Davignon J
    Atherosclerosis; 1985 Jun; 55(3):353-6. PubMed ID: 4015753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
    Valeri A; Gelfand J; Blum C; Appel GB
    Am J Kidney Dis; 1986 Dec; 8(6):388-96. PubMed ID: 3544820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of probucol on cholesterol metabolism in the rat.
    Li JR; Holets RJ; Kottke BA
    Atherosclerosis; 1980 Aug; 36(4):559-65. PubMed ID: 7417372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term effects of probucol on serum lipid levels.
    McCaughan D
    Arch Intern Med; 1981 Oct; 141(11):1428-32. PubMed ID: 7025778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of long-term probucol intake on the lipoprotein cholesterol content and glutathione peroxidase activity in the blood of patients with coronary arteriosclerosis and hyperlipidemia].
    Lankin VZ; Revenko VM; Lupanov VP; Tikhaze AK; Liakishev AA; Kukharchuk VV
    Kardiologiia; 1993; 33(9):41-4, 4-5. PubMed ID: 8145441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A little more information about aggravation of probucol-induced HDL-reduction by clofibrate.
    Yokoyama S; Yamamoto A; Kurasawa T
    Atherosclerosis; 1988 Mar; 70(1-2):179-81. PubMed ID: 3355613
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H; Izumino K; Asaka M; Fujita M; Nishino A; Sasayama S
    Nephron; 1987; 47(4):280-3. PubMed ID: 3696330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of probucol on serum cholesterol concentration in primary hyperlipoproteinemia].
    Kawecka-Jaszcz K; Kocemba J; Wasowicz B; Król W
    Kardiol Pol; 1982; 25(5-6):377-82. PubMed ID: 6759746
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative study of bezafibrate and probucol in hyperlipidaemia.
    Páez Moreno JP; González G
    Curr Med Res Opin; 1989; 11(8):523-32. PubMed ID: 2680288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.